Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 9.15 USD -1.4%
Market Cap: 457.5m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

TBPH Price Targets Summary
Theravance Biopharma Inc

Wall Street analysts forecast TBPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TBPH is 15.56 USD with a low forecast of 10.1 USD and a high forecast of 25.2 USD.

TBPH Lowest Forecast
Wall Street Target
10.1 USD
10% Upside
TBPH Average Forecast
Wall Street Target
15.56 USD
70% Upside
TBPH Highest Forecast
Wall Street Target
25.2 USD
175% Upside
Lowest
Price Target
10.1 USD
10% Upside
Average
Price Target
15.56 USD
70% Upside
Highest
Price Target
25.2 USD
175% Upside
Theravance Biopharma Inc Competitors:
Price Targets
RX
Biosyent Inc
1% Upside
4577
Daito Pharmaceutical Co Ltd
104% Upside
Z
300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
37% Upside
4886
ASKA Pharmaceutical Holdings Co Ltd
15% Upside
RX
Biosyent Inc
1% Upside
4577
Daito Pharmaceutical Co Ltd
104% Upside
Z
300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
37% Upside
4886
ASKA Pharmaceutical Holdings Co Ltd
15% Upside
CAPLIPOINT
Caplin Point Laboratories Ltd
16% Upside
O
ORNBV
Orion Oyj
2% Downside
I
IMP
Imexpharm Corp
12% Downside
300705
Hunan Jiudian Pharmaceutical Co Ltd
112% Upside

Revenue
Forecast

Revenue Estimate
Theravance Biopharma Inc

For the last 8 years the compound annual growth rate for Theravance Biopharma Inc's revenue is 4%. The projected CAGR for the next 3 years is 19%.

4%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Theravance Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Theravance Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
12%
Average Beat
What are analyst estimates?

See Also

Summary
TBPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
TBPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TBPH stock valuation using valuation multiples.
Wall Street Estimates
TBPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TBPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TBPH's stock price target?
Price Target
15.56 USD

According to Wall Street analysts, the average 1-year price target for TBPH is 15.56 USD with a low forecast of 10.1 USD and a high forecast of 25.2 USD.

What is Theravance Biopharma Inc's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Theravance Biopharma Inc's revenue is 4%. The projected CAGR for the next 3 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.